DNA Electronics
DNAe develops a cartridge-based, semiconductor (microchip) sequencing platform designed for rapid, direct-from-specimen genomic analysis at or near the point of care. The company focuses on infectious disease (bloodstream infection and antimicrobial resistance) and is expanding applications into viral detection and oncology (liquid biopsy/ctDNA). DNAe reports a fully automated, sample-to-report workflow and engages with clinical partners through early access programs and trials.
Industries
Nr. of Employees
medium (51-250)
DNA Electronics
Scale Space, 58 Wood Lane, London W12 7RZ, United Kingdom
Products
LiDia-SEQ platform
A cartridge-based, automated sample-to-report sequencing platform that performs direct-from-specimen genomic analysis on a semiconductor microchip and produces identified pathogens, resistance markers or genomic findings for clinical use (development-stage).
LiDia-SEQ platform
A cartridge-based, automated sample-to-report sequencing platform that performs direct-from-specimen genomic analysis on a semiconductor microchip and produces identified pathogens, resistance markers or genomic findings for clinical use (development-stage).
Services
Collaborative program providing early access to assays and prototype systems: Phase One offers sample testing (whole blood and isolates) performed by the company for research use; Phase Two plans placement of prototype systems in selected hospitals for on-site testing prior to commercial launch.
Collaborative program providing early access to assays and prototype systems: Phase One offers sample testing (whole blood and isolates) performed by the company for research use; Phase Two plans placement of prototype systems in selected hospitals for on-site testing prior to commercial launch.
Expertise Areas
- Point-of-care / near-patient sequencing diagnostics
- Infectious disease and antimicrobial resistance diagnostics
- Bloodstream infection (sepsis) diagnostics
- NGS assay development
Key Technologies
- Semiconductor (chip-based) sequencing
- Next-generation sequencing (NGS)
- Cartridge-based automated sample-to-result workflows
- Lab-on-a-chip / microfluidics
News & Updates
Presentation of new data on the LiDia-SEQ platform for oncology monitoring, BSI and AMR at AMP 2025 in Boston; company hosted meetings with senior leadership.
Planned presentations and meetings at IDWeek 2025 in Atlanta, including a diagnostic pipeline presentation.
Posters on BSI/AMR and ctDNA methods presented at AMP 2024; posters accepted for publication in The Journal of Molecular Diagnostics.
Company Q&A covering LiDia-SEQ platform status, sample-to-result capabilities, clinical validation plans, regulatory strategy and commercial timelines (first-phase launch planned early 2027 for research use).
Internal testing using synthesized SARS-CoV-2 material and automated cartridge workflows demonstrated sequencing and identification of SARS-CoV-2-representative samples.
Summary of 2023 development milestones, device data demonstrating direct-from-whole-blood sequencing, and senior hires to support commercialization.
Presentation of new data on the LiDia-SEQ platform for oncology monitoring, BSI and AMR at AMP 2025 in Boston; company hosted meetings with senior leadership.
Planned presentations and meetings at IDWeek 2025 in Atlanta, including a diagnostic pipeline presentation.
Posters on BSI/AMR and ctDNA methods presented at AMP 2024; posters accepted for publication in The Journal of Molecular Diagnostics.
Company Q&A covering LiDia-SEQ platform status, sample-to-result capabilities, clinical validation plans, regulatory strategy and commercial timelines (first-phase launch planned early 2027 for research use).
Internal testing using synthesized SARS-CoV-2 material and automated cartridge workflows demonstrated sequencing and identification of SARS-CoV-2-representative samples.
Summary of 2023 development milestones, device data demonstrating direct-from-whole-blood sequencing, and senior hires to support commercialization.